Perspective
Jul. 1, 2016
Fixing the generic regulatory process
If it passes, the CREATES bill will help bring generic drugs to market more quickly. By Robin Feldman
Robin Feldman
Professor
UC Hastings College of the Law
Robin is director of the Institute for Innovation Law at UC Hastings College of the Law.
Medicines are making headlines these days, not for their breathtaking ability to save lives but for their soaring prices. When those high prices result from manipulation of a regulatory process, that is a problem. Thus, I am heartened to see the Senate contemplating legislation to fix one part of the regulatory process that helps bring generic drugs to market.
For 30 years, the Hatch-Waxman Act has provided an expedited path...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In